Free Design Audit Available - Click Here for Details

Orthofix launches OsteoCove bioactive synthetic graft

Orthofix today announced it received FDA 510(k) clearance for its OsteoCove bioactive synthetic graft.

The graft is available in both a putty and strip configuration and Orthofix designed it to provide superior bone-forming capabilities with handling characteristics for a wide range of spine and orthopedic procedural applications.

“Using the same disciplined R&D approach we have historically taken with our internally processed demineralized bone matrix solutions, we created a product that challenges the performance expectations of typical synthetic bone graft substitutes,” said Orthofix Chief Scientific Officer Frank Vizesi. “OsteoCove is another prime example of leveraging our strengths in product development in combination with our vertically integrated manufacturing expertise.”

OsteoCove is made of biphasic ceramic granule that is comprised of β-tricalcium phosphate (ß-TCP) and hydroxyapatite (HA) combined with type-I bovine collagen. The topography is designed to elicit a bone-forming response. The company said the specialized surface chemistry and microporosity are shown to promote superior bone formation when compared to other commercially available advanced synthetic grafts.

Sign up for Blog Updates